These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 36082729

  • 1. Heart Failure with Preserved Ejection Fraction: Management Guidelines (From Heart Failure Association of India, Endorsed by Association of Physicians of India).
    S H, Oomman A, Jadhav UM, Raghuraman B, Mohanan PP, Tiwaskar M, Wander GS, Chopra VK.
    J Assoc Physicians India; 2022 Aug; 70(8):11-12. PubMed ID: 36082729
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV.
    JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
    [Abstract] [Full Text] [Related]

  • 3. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Aimo A, Pateras K, Stamatelopoulos K, Bayes-Genis A, Lombardi CM, Passino C, Emdin M, Georgiopoulos G.
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
    [Abstract] [Full Text] [Related]

  • 4. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan Ö, Dukat A, Lefkowitz MP, McMurray JJ.
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [Abstract] [Full Text] [Related]

  • 5. Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction.
    Raschi E, Diemberger I, Sabatino M, Poluzzi E, De Ponti F, Potena L.
    Expert Opin Pharmacother; 2022 Feb; 23(3):303-320. PubMed ID: 35050813
    [Abstract] [Full Text] [Related]

  • 6. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
    Yang M, Butt JH, Kondo T, Jering KS, Docherty KF, Jhund PS, de Boer RA, Claggett BL, Desai AS, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Langkilde AM, Martinez FA, Petersson M, Shah SJ, Vaduganathan M, Wilderäng U, Solomon SD, McMurray JJV.
    Eur J Heart Fail; 2022 Dec; 24(12):2307-2319. PubMed ID: 36342375
    [Abstract] [Full Text] [Related]

  • 7. New therapies for the treatment of heart failure with preserved ejection fraction.
    Meier ML, Pierce KN.
    Am J Health Syst Pharm; 2022 Aug 19; 79(17):1424-1430. PubMed ID: 35524990
    [Abstract] [Full Text] [Related]

  • 8. Severe Hypotension With Concomitant Sodium-Glucose Co-Transporter-2 Inhibitor and Angiotensin Receptor-Neprilysin Inhibitor Therapy in a Patient With Heart Failure Reduced Ejection Fraction: A Case Report.
    Schumacher C.
    J Pharm Pract; 2024 Apr 19; 37(2):495-499. PubMed ID: 36441976
    [Abstract] [Full Text] [Related]

  • 9. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension.
    Codina P, Domingo M, Barceló E, Gastelurrutia P, Casquete D, Vila J, Abdul-Jawad Altisent O, Spitaleri G, Cediel G, Santiago-Vacas E, Zamora E, Ruiz-Cueto M, Santesmases J, de la Espriella R, Pascual-Figal DA, Nuñez J, Lupón J, Bayes-Genis A.
    ESC Heart Fail; 2022 Aug 19; 9(4):2170-2180. PubMed ID: 35588235
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS, Zannad F, Claggett B, Mc Causland FR, Ferreira JP, Desai A, Barkoudah E, McMurray JJV, Pfeffer MA, Solomon SD.
    JACC Heart Fail; 2021 Jan 19; 9(1):13-24. PubMed ID: 33189633
    [Abstract] [Full Text] [Related]

  • 11. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA, Brown NJ.
    Circulation; 2016 Mar 15; 133(11):1115-24. PubMed ID: 26976916
    [Abstract] [Full Text] [Related]

  • 12. The contemporary role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of heart failure: State-of-the-art review.
    Ezhumalai B, Modi R, Panchanatham M, Kaliyamoorthy D.
    Indian Heart J; 2024 Mar 15; 76(4):229-239. PubMed ID: 39009078
    [Abstract] [Full Text] [Related]

  • 13. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O'Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD, PARAGON-HF Investigators.
    J Am Coll Cardiol; 2019 Dec 10; 74(23):2858-2873. PubMed ID: 31806129
    [Abstract] [Full Text] [Related]

  • 14. Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
    Hammerman A, Azuri J, Aboalhasan E, Arbel R.
    Am J Cardiovasc Drugs; 2022 May 10; 22(3):325-331. PubMed ID: 34671945
    [Abstract] [Full Text] [Related]

  • 15. Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
    Kuno T, Ueyama H, Fujisaki T, Briasouli A, Takagi H, Briasoulis A.
    Am J Cardiol; 2020 Apr 15; 125(8):1187-1193. PubMed ID: 32081366
    [Abstract] [Full Text] [Related]

  • 16. Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
    Lyle MA, Iyer SR, Redfield MM, Reddy YNV, Felker GM, Cappola TP, Hernandez AF, Scott CG, Burnett JC, Pereira NL.
    JACC Heart Fail; 2020 Jan 15; 8(1):70-80. PubMed ID: 31392960
    [Abstract] [Full Text] [Related]

  • 17. Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry.
    Pierce JB, Li Z, Greiner MA, Lippmann SJ, Hardy NC, Shen X, Stampehl M, Mentz RJ, Allen LA, Peterson PN, Fonarow GC, O'Brien EC, Greene SJ.
    Circ Heart Fail; 2023 Jan 15; 16(1):e010176. PubMed ID: 36314141
    [No Abstract] [Full Text] [Related]

  • 18. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Kario K.
    Curr Cardiol Rep; 2018 Jan 27; 20(1):5. PubMed ID: 29374807
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, PARAGON-HF Investigators and Committees.
    N Engl J Med; 2019 Oct 24; 381(17):1609-1620. PubMed ID: 31475794
    [Abstract] [Full Text] [Related]

  • 20. Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
    Packer M, Kitzman DW.
    JACC Heart Fail; 2018 Aug 24; 6(8):633-639. PubMed ID: 29525327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.